In our most recent paper, we show that administration of a pharmacologically optimized enzyme (PEGylated kynureninase; hereafter referred to as PEG-KYNase) that degrades Kyn into immunologically inert, nontoxic and readily cleared metabolites inhibits tumor growth. Enzyme treatment was associated with a marked increase in the tumor infiltration and proliferation of polyfunctional CD8+ lymphocytes. We show that PEG-KYNase administration had substantial therapeutic effects when combined with approved checkpoint inhibitors or with a cancer vaccine for the treatment of large B16-F10 melanoma, 4T1 breast carcinoma or CT26 colon carcinoma tumors. PEG-KYNase mediated prolonged depletion of Kyn in the TME and reversed the modulatory effects of IDO1/TDO upregulation in the TME.
- Our Covid Research Featured on NIH Director’s Blo...May 18, 2021 - 4:40 PM
- The Institute a Member of the Nationwide NIH COVID-19 S...October 8, 2020 - 11:25 PM
- Drs. Ippolito and Lavinder featured in the Austin American...September 23, 2020 - 2:17 PM
- Institute Develops Antibody Test for COVID-19 That is Sensitive,...September 13, 2020 - 4:19 PM